Company profile for RadioMedix

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

RadioMedix, Inc. is a clinical-stage biotechnology company, based in Texas, focused on innovative targeted radiopharmaceuticals for diagnosis, monitoring, and therapy of cancer. We commercialize radiopharmaceuticals for PET imaging and targeted alpha and beta-emitter therapy. Our operations cover the entire value chain from drug discovery to sponsoring and conducting clinical trials to scale up manufacturing. RadioMedix is c...
RadioMedix, Inc. is a clinical-stage biotechnology company, based in Texas, focused on innovative targeted radiopharmaceuticals for diagnosis, monitoring, and therapy of cancer. We commercialize radiopharmaceuticals for PET imaging and targeted alpha and beta-emitter therapy. Our operations cover the entire value chain from drug discovery to sponsoring and conducting clinical trials to scale up manufacturing. RadioMedix is compliant with 21 CFR Parts 210,211,212. Our Molecular Core Facility supports the synthesis, and the pre-clinical evaluation of our drugs and contract projects.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
9701 Richmond Avenue, Suite 222 Houston, Texas 77042
Telephone
Telephone
713-358-6500
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/12/04/3199634/0/en/RadioMedix-and-Thor-Medical-enter-supply-agreement-for-thorium-228.html

GLOBENEWSWIRE
04 Dec 2025

https://www.globenewswire.com/news-release/2025/09/11/3148395/0/en/RadioMedix-and-Vect-Horus-Announce-First-Patient-Dosed-in-Exploratory-Clinical-Study-of-203Pb-RMX-VH-PIB-for-Glioblastoma-Multiforme-and-Pancreatic-Ductal-Adenocarcinoma.html

GLOBENEWSWIRE
11 Sep 2025

https://www.globenewswire.com/news-release/2025/06/12/3098408/0/en/RadioMedix-Debuts-Proprietary-bench-top-Pb-Generator-to-Support-Targeted-Alpha-Therapy-Development.html

GLOBENEWSWIRE
12 Jun 2025

https://www.globenewswire.com/news-release/2024/09/12/2944919/0/en/Press-Release-Sanofi-RadioMedix-and-Orano-Med-announce-licensing-agreement-on-next-generation-radioligand-medicine-for-rare-cancers.html

GLOBENEWSWIRE
12 Sep 2024

https://www.businesswire.com/news/home/20240212199538/en

BUSINESSWIRE
12 Feb 2024

https://www.globenewswire.com/news-release/2023/02/15/2608809/0/en/RadioMedix-Inc-Announces-the-Acquisition-of-its-225Ac-PSMA-I-T-program-a-Targeted-Alpha-Therapy-TAT-for-Metastatic-Castration-Resistant-Prostate-Cancer-by-Fusion-Pharmaceuticals-In.html

GLOBENEWSWIRE
15 Feb 2023

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty